Search

Displaying results 1571 - 1580 of 5261 in total
  1. Drug

    Oxaliplatin

    go.drugbank.com/drugs/DB00526
    ApprovedInvestigational

    [A797] Oxaliplatin was approved by the FDA on January 9, 2004 and is currently marketed by Sanofi-Aventis under the trademark Eloxatin®.[L47316] … [A797] However, this leads to poorer water solubility, which was compensated by the addition of the chloride moieties.

    Synonyms: (SP-4-2-(1R-TRANS))-(1,2-CYCLOHEXANEDIAMINE-N,N')(ETHANEDIOATO(2-)-O,O')PLATINUM
  2. Drug

    Tedizolid phosphate

    go.drugbank.com/drugs/DB09042
    Approved

    [L11232, A199086, A199050] Tedizolid was approved by the FDA on June 20, 2014, for sale by Cubist Pharmaceuticals as tedizolid phosphate (SIVEXTRO®).

  3. Drug

    Glycine

    go.drugbank.com/drugs/DB00145
    ApprovedInvestigationalNutraceuticalVet approved

    A non-essential amino acid. It is found primarily in gelatin and silk fibroin and used therapeutically as a nutrient. It is also a fast inhibitory neurotransmitter.

    Mixtures: Vamin N, AMINOSTERIL N-HEPA 8%
  4. Drug

    Panobinostat

    go.drugbank.com/drugs/DB06603
    ApprovedInvestigational

    Panobinostat is marketed by Novartis under the brand name Farydak. … Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma.

    Synonyms: (2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]acrylamide, 2-PROPENAMIDE, N-HYDROXY-3-(4-(((2-(2-METHYL-1H-INDOL-3-YL)ETHYL)AMINO)METHYL)PHENYL)-, (2E)-
  5. Drug

    Prednicarbate

    go.drugbank.com/drugs/DB01130
    Approved

    It has a favorable benefit-risk ratio, with an inflammatory action similar to that of a medium potency corticosteroid, but with a low potential to cause skin atrophy.

  6. Drug

    Lazertinib

    go.drugbank.com/drugs/DB16216
    ApprovedInvestigational

    [A264289] It was approved by the FDA on August 19, 2024.[L51189] Lazertinib is used alone or in combination with other chemotherapeutic agents.[L51184]

    Synonyms: N-(5-((4-(4-((DIMETHYLAMINO)METHYL)-3-PHENYL-1H-PYRAZOL-1-YL)PYRIMIDIN-2-YL)AMINO)-4-METHOXY-2-MORPHOLINOPHENYL)ACRYLAMIDE, 2-PROPENAMIDE, N-(5-((4-(4-((DIMETHYLAMINO)METHYL)-3-PHENYL-1H-PYRAZOL-1-YL)-2-PYRIMIDINYL)AMINO)-4-METHOXY-2-(4-MORPHOLINYL)PHENYL)-
  7. Drug

    Flupentixol

    go.drugbank.com/drugs/DB00875
    ApprovedInvestigationalWithdrawn

    It is approved for use in Canada and other countries around the world, but not in the US. … Flupentixol decanoate is one of the active ingredients found in injectable drug formulations: it is produced by esterification of cis(Z)‐flupentixol with decanoic acid.

  8. Drug

    Neisseria meningitidis serogroup B recombinant LP2086 A05 protein variant antigen

    go.drugbank.com/drugs/DB10284
    ApprovedInvestigational

    It is contained in the suspension of Trumenba, which is a vaccine is composed of two recombinant lipidated factor H binding protein (fHBP) variants from N. meningitidis serogroup B, one from fHBP subfamily … A and one from subfamily B (A05 and B01, respectively).

  9. Drug

    Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen

    go.drugbank.com/drugs/DB10990
    Approved

    The vaccine contains Haemophilus b capsular polysaccharide (polyribosyl-ribitol-phosphate [PRP]), which is a high molecular weight polymer prepared from the *Haemophilus influenzae* type b strain 20,752

  10. Drug

    Allogeneic processed thymus tissue

    go.drugbank.com/drugs/DB16736
    Approved

    [L38929] Congenital athymia is a rare condition that leads to the absence of a thymus at birth and a high premature mortality rate, with patients typically dying by age two or three. … Allogeneic processed thymus tissue implantation works by migrating the recipient’s bone marrow-derived stem cells to the implanted cultured thymus tissue that develops immunocompetent naïve T cells.